Premium
Mass spectrometry as a technique for testing the purity of drugs for biological use: The case of new antitumor cyclophosphazenes
Author(s) -
Monsarrat Bernard,
Promé JeanClaude,
Labarre JeanFrançois,
Sournies François,
van de Grampel Johan C.
Publication year - 1980
Publication title -
biomedical mass spectrometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 121
eISSN - 1096-9888
pISSN - 0306-042X
DOI - 10.1002/bms.1200070910
Subject(s) - chlorine atom , mass spectrometry , impurity , mass spectrum , chemistry , decomposition , chlorine , ion , analytical chemistry (journal) , chromatography , combinatorial chemistry , medicinal chemistry , organic chemistry
Mass spectrometry has been used for testing the chemical purity of some new antitumor cyclophosphazene compounds. The spectrum of N 3 P 3 Az 6 (code name MYKO 63)—which exhibits noticeable activity on murine P 388, L 1210 and B 16 tumors—appeared to be remarkably simple, as most of the fragmentations arose from successive losses of the aziridino radicals. Traces of the pentaziridinomonochloro impurity formed by an incomplete substitution of N 3 P 3 Cl 6 chlorine atoms under aziridinolysis could be detected in an impure and toxic sample by spectral subtraction. Quantification of this impurity was performed by selected ion monitoring in the direct inlet mode of sample introduction. The mass spectra of other derivatives of this class of compounds are slightly more complex, since the decomposition pathways showed more intense H‐transfers associated with the loss of substituents.